References in periodicals archive ?
Biopharmaceutical company Galmed Pharmaceuticals Ltd (Nasdaq: GLMD) announced on Tuesday that it has raised approximately USD11.6m in gross proceeds during December 2017, under its at-the-market programmes.
STIFEL STARTS GALMED WITH A BUY: Stifel analyst Adam Walsh initiated Galmed (GLMD) with a Buy rating and $35 price target, calling it a "legitimate late-stage NASH play" after Aramchol recently proved itself in a Phase 2 trial as a clearly active and "very safe" compound for treating NASH.
Galmed (GLMD), up 14% after Stifel analyst Adam Walsh initiated the stock with a Buy rating and $35 price target, calling it a "legitimate late-stage NASH play"...
Galmed Pharmaceuticals Ltd (Nasdaq: GLMD), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of non-alcoholic steatohepatitis and other liver diseases, has announced its financial results for the first quarter of 2017, it was reported yesterday.
Cantor Fitzgerald analyst Elemer Piros last night initiated coverage of Galmed Pharmaceuticals (GLMD) with an Overweight rating and $59 price target.
Galmed Pharmaceuticals Ltd (Nasdaq: GLMD), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, has named Liat Hayardeny, PhD, MBA, as Chief Scientific Officer effective 7 September 2016, it was reported yesterday.
ALSO HIGHER: Galmed (GLMD), up 168% after announcing top-line, 52-week results from the global Phase 2b ARREST study in NASH patients...
Maxim analyst Jason McCarthy raised his outyear estimates for Aramchol and reduced his risk adjustment to 15% from 30% following the announcement of Galmed's (GLMD) Phase 2b data for Aramchol in NASH.
Acronyms browser ?
Full browser ?